Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX6RZG)

Drug Name

EFT508 Drug Info

Synonyms

Tomivosertib; eFT508; 1849590-01-7; EFT-508; UNII-U2H19X4WBV; U2H19X4WBV; Tomivosertib [INN]; Tomivosertib [USAN]; SCHEMBL17362622; GTPL10167; eFT-508 (eFT508); EFT 508; MolPort-044-560-418; BCP18993; EX-A2494; ZINC575623807; AKOS030627405; CS-5841; compound 23 [PMID: 29526098]; HY-100022; S8275; 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-1'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'(2'H)-dione; 6-[(6-aminopyrimidin-4-yl)amino]-8-methylspiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 2	[1]
Hepatocellular carcinoma	2C12.02	Phase 2	[1]
Triple negative breast cancer	2C60-2C65	Phase 2	[1]
Lymphoma	2A80-2A86	Phase 1/2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

Cross-matching ID

PubChem CID: 118598754
CAS Number: CAS 1849590-01-7
TTD Drug ID: DMX6RZG

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
MAP kinase signal-integrating kinase 2 (MKNK2)	TTRECN3	MKNK2_HUMAN	Inhibitor	[1]
MAPK signal-integrating kinase 1 (MKNK1)	TTEZAUX	MKNK1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)